



Paladin Labs Announces the Canadian Launch of Zincofax® Spray

February 9, 2015

MONTREAL, Feb. 9, 2015 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: [ENDP](#)) (TSX: ENL), announced today the launch of **Zincofax® Spray**, a new, spray-on ointment from the makers of **Zincofax®**, the trusted and established brand for diaper rash ointments.

New Zincofax® Spray is the first OTC branded diaper rash spray-on ointment in Canada.

Diaper rashes can occur intermittently, anytime a child wears diapers, but they are more common in babies during their first 15 months, especially between 9 and 12 months of age¹. The most common cause of diaper rash is soiled diapers, whether cloth or disposable, which create a warm, damp environment that can cause irritation and promote infection¹.

"We are pleased to announce the launch of Zincofax® Spray in Canada," said Mark Beaudet, President of Paladin Labs Inc. "This new format will offer a convenient, mess-free alternative to applying diaper rash ointments."

Paladin obtained the exclusive rights to market and sell **Zincofax® Spray** in Canada, The Republic of South Africa and Mexico from Oystershell Laboratories in May 2013.

About Zincofax®

Zincofax® is the #1 pharmacist recommended brand in Canada for diaper rash treatment². This rich, creamy ointment glides smoothly on tender skin to form a protective barrier without causing discomfort to the baby. Available in Spray, Original, Extra-Strength and Fragrance-Free formulas, **Zincofax®** has been used by parents to treat diaper rash since 1945.

For more information, please visit www.zincofax.ca.

Zincofax® Spray suggested retail price: \$11.99-13.99 (100ml Bottle). Available on pharmacy shelves.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Learn more at www.endo.com.

References

1 Mayo Foundation for Medical Education and Research.

2 Pharmacy practice + (Vol.1 No.3) April 2014

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward-looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein or therein, could affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in Endo's Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the

aggregate, could cause Endo's actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

SOURCE Endo International plc

For further information: Investors/Media: Keri P. Mattox, (484) 216-7912; Investors: Jonathan Neely, (484) 216-6645, Media: Heather Zoumas-Lubeski, (484) 216-6829